Ten Years of Ocrelizumab in Relapsing Multiple Sclerosis: The OPERA I and II Randomized Clinical Trials. (PubMed, JAMA Neurol) - Oct 6, 2026 - P3 | "In the OPERA I and II randomized clinical trials, continuous OCR treatment over 10 years provided greater benefit in preserving function than a 2-year delay in initiating OCR, reinforcing the importance of early high-efficacy treatment. ClinicalTrials.gov Identifiers: NCT01247324 and NCT01412333."
Clinical • Journal • CNS Disorders • Infectious Disease • Multiple Sclerosis
|
|
Amit Bar-Or; Cathy Chognot; Christine Lebrun-Frenay; Douglas L Arnold; Gavin Giovannoni; Hans-Martin Schneble; Licinio Craveiro; Lilyana Amezcua; Ludwig Kappos; Luisa M Villar; Martin S Weber; Massimo Filippi; Noemi Pasquarelli; Qing Wang; Stephen L Hauser; Xavier Montalban
|